Bleeding risk with clopidogrel and percutaneous endoscopic gastrostomy

Umair Sohail1, Chela Harleen1, Amin O Mahdi1

  • 1Umair Sohail, Chela Harleen, Amin O Mahdi, Murtaza Arif, Matthew L Bechtold, Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri, Columbia, MO 65212, United States.

Insights

Recent clopidogrel use did not increase bleeding risk in patients undergoing percutaneous endoscopic gastrostomy (PEG). This study found no significant differences in bleeding complications between PEG patients with or without clopidogrel.

Area of Science:

  • Gastroenterology
  • Cardiology
  • Internal Medicine

Background:

  • Percutaneous endoscopic gastrostomy (PEG) is a common procedure.
  • Clopidogrel is an antiplatelet medication often used in patients with cardiovascular conditions.
  • The safety of PEG in patients recently using clopidogrel requires evaluation.

Purpose of the Study:

  • To compare the incidence of bleeding within 48 hours after percutaneous endoscopic gastrostomy (PEG) in patients who were taking clopidogrel versus those who were not.

Main Methods:

  • A retrospective, single-center study included adult patients who underwent PEG between January 2008 and January 2014.
  • Patients were divided into two groups: those taking clopidogrel within 5 days of PEG and those not taking clopidogrel within 5 days of PEG.
  • Bleeding outcomes, including hematochezia, melena, hematemesis, hemoglobin decrease, blood transfusions, and repeat endoscopy, were assessed within 48 hours post-procedure.

Main Results:

  • Out of 319 PEG patients, 33 were on clopidogrel and 286 were not.
  • No patients in either group experienced hematochezia, melena, or hematemesis within 48 hours of PEG.
  • There were no statistically significant differences between the clopidogrel and non-clopidogrel groups regarding hemoglobin decrease (> 2 g/dL), blood transfusions, or need for repeat endoscopy for bleeding.

Conclusions:

  • Recent use of clopidogrel is not associated with a significant increase in post-procedure bleeding complications after percutaneous endoscopic gastrostomy (PEG).
  • The findings suggest that PEG can be safely performed in patients recently treated with clopidogrel.
Abstract

Related Concept Videos

Endoscopic Procedures I: Esophagogastroduodenoscopy01:29

Endoscopic Procedures I: Esophagogastroduodenoscopy

An Esophagogastroduodenoscopy (EGD) is a diagnostic procedure in which an endoscopist uses a flexible, lighted endoscope to visualize the upper gastrointestinal (GI) tract. The procedure includes visualizing the oropharynx, esophagus, stomach, and the first part of the small intestine, the duodenum.
During an EGD, the endoscope can be used to:
1.8K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
723
Endoscopic Procedures V: ERCP01:26

Endoscopic Procedures V: ERCP

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...
5.0K
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
893
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
1.1K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
607